Invivyd (NASDAQ:IVVD – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright ...
Invivyd (NASDAQ:IVVD – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a ...
In a report released today, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Invivyd (IVVD – Research Report), with a price ...
H.C. Wainwright maintains a Buy rating on Invivyd (IVVD) with a $10 price target after the FDA rejected its submission to expand Pemgarda’s ...
Invivyd's bid to expand Pemgarda's EUA for COVID-19 treatment was denied by the FDA. The company will share new data on ...
FDA's reasoning appears to center on a belief that COVID-19 treatment immunobridging analyses for a monoclonal antibody (mAb) must meet a standard of superior antiviral activity rather than equivalent ...
Monday said that its request to expand the existing emergency use authorization of PEMGARDA (pemivibart) to include treatment of mild-to-moderate COVID-19 for immunocompromised persons who have no ...
We recently compiled a list of the 10 Micro and Small-Cap Firms Drive Year-to-Date Gains. In this article, we are going to ...
WALTHAM, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc Elia, Chairman of the Invivyd Board of Directors, will be presenting at the Oppenheimer 35th ...